AMHERST, Mass. – A University of Massachusetts Amherst team at the New England Regional Center of Vector-borne Diseases (NEWVEC) announced new research into a medical therapy that may be effective at treating Lyme disease.
The therapy is used to inhibit the growth of cancer cells. Lyme disease, the most common vector-borne disease in the U.S., is spread by infected deer ticks and doesn’t always respond to antibiotics.
Stephen Rich, professor of microbiology and executive director of NEWVEC, said that the therapy is a long way away, but early findings are encouraging.
“There are people who have cases of Lyme disease that go on and on,” Rich said. “So there’s always interest in finding new therapies or new ways to inhibit the growth of the bacterium. And based on what we’re seeing in the lab, this may be one of those ways.”
Rich said the research will continue at NEWVEC, which was funded by the Centers for Disease Control and Prevention with a $10 million award to prevent and reduce tick- and mosquito-borne diseases in New England.
